Glomerulonephritis after Alemtuzumab Treatment for Multiple Sclerosis: A Report of Two Cases
Introduction: Alemtuzumab, a humanized monoclonal antibody indicated for the treatment of adult patients with active relapsing-remitting multiple sclerosis (MS), has been associated with increased risk of autoimmune adverse events, including thyroid disorders, immune thrombocytopenia, and renal dise...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2024-04-01
|
| Series: | Glomerular Diseases |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/538492 |